Lung Cancer

As knowledge of lung cancer tumor cell biology has evolved, small-molecule drugs that target specific genetic mutations offer oncologists the opportunity to treat patients with NSCLC in a personalized fashion.
Chicago, IL—Alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, was called a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer (NSCLC), based on results of the phase 3 ALEX clinical trial, which were presented at the 2017 ASCO annual meeting.
Chicago, IL—Osimertinib (Tagrisso) extends progression-free survival (PFS) compared with standard chemotherapy in patients with EGFR T790M mutation–positive non–small-cell lung cancer (NSCLC) who have central nervous system (CNS) metastases, reported Marina C. Garassino, MD, Thoracic Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, at the 2017 ASCO annual meeting.
Dr. Edward Garon discusses the use of PD-1 and PD-L1 inhibitors in patients with lung cancer.
Dr. Edward Garon does not believe there is much value in utilizing PD-L1 inhibitors for pateints with ALK gene rearrangement.
Dr. Edward Garon believes it's important to recognize that agents without efficacy are not beneficial to the patient despite low toxicity.
Dr. Edward Garon shares an anecdote about an interesting NSCLC case from his practice.
Dr. Edward Garon provides an overview of the most common presenting clinical features in adults with non-small cell lung cancer (NSCLC).
Dr. Edward Garon speaks about how differences in patient populations with lung cancer can make it difficult to interpret and act on data.
Dr. Edward Garon explains how he discusses immunotherapies with patients.
Page 1 of 3
Results 1 - 10 of 27
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME